September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Two year visual outcomes in patients with neovascular age-related macular degeneration treated with ranibizumab stratified by patient age and baseline visual acuity
Author Affiliations & Notes
  • Elewys Hearne
    Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Farid Afshar
    Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Emily Fletcher
    Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Quresh Mohamed
    Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Rob Johnston
    Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom
  • Footnotes
    Commercial Relationships   Elewys Hearne, None; Farid Afshar, None; Emily Fletcher, None; Quresh Mohamed, None; Rob Johnston, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 548. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Elewys Hearne, Farid Afshar, Emily Fletcher, Quresh Mohamed, Rob Johnston; Two year visual outcomes in patients with neovascular age-related macular degeneration treated with ranibizumab stratified by patient age and baseline visual acuity. Invest. Ophthalmol. Vis. Sci. 2016;57(12):548.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report 2 year visual outcomes stratified by age and baseline visual acuity in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal ranibizumab in Gloucestershire NHS trust, UK.

Methods : Data was collected prospectively using an electronic patient record system. Baseline visual acuity (VA) was categorised as under 35 letters, 35-55 letters, 56-70 letters and over 70 letters.

Results : In the groups with VA over 56 letters at baseline there was a slight deterioration in vision over 2 years. In the 56-70 letter group mean VA at baseline was 64.6 letters and 59.6 letters at 2 years. In the over 70 letters group mean VA was 74.7 letters and 70.3 letters respectively. <span style="line-height:1.6">In the 35-55 letters group mean VA remained stable from 45.2 to 43.9 letters. In the under 35 letters group mean VA improved from 24.4 to 27.5 letters (Figure 1). This pattern was reflected for baseline VA in the age groups 71-80, 81-90 and over 91. The largest improvement in mean VA was found in patients under 70 years old in the lower baseline VA groups. In patients aged under 70 years old mean VA in the under 35 letters group and 35-55 letters group improved from 25.5 to 59.4, and 47.1 to 59.8 letters respectively (Figure 2).

Conclusions : This large data set identifies that visual outcome in patients with nAMD treated with intravitreal ranibizumab is dependent on baseline visual acuity. The greatest improvement in visual outcome is found in younger patients with poor visual acuity at baseline.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Mean visual acuity of neovascular age-related macular degeneration patients of all ages, over time by baseline visual acuity groups, during the 2 year treatment with ranibizumab.

Mean visual acuity of neovascular age-related macular degeneration patients of all ages, over time by baseline visual acuity groups, during the 2 year treatment with ranibizumab.

 

Mean visual acuity of neovascular age-related macular degeneration patients aged under 70 years old, over time by baseline visual acuity groups, during the 2 year treatment with ranibizumab.

Mean visual acuity of neovascular age-related macular degeneration patients aged under 70 years old, over time by baseline visual acuity groups, during the 2 year treatment with ranibizumab.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×